Amanda L. Huff

710 total citations
17 papers, 267 citations indexed

About

Amanda L. Huff is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Amanda L. Huff has authored 17 papers receiving a total of 267 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Immunology and 4 papers in Molecular Biology. Recurrent topics in Amanda L. Huff's work include CAR-T cell therapy research (11 papers), Immunotherapy and Immune Responses (9 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Amanda L. Huff is often cited by papers focused on CAR-T cell therapy research (11 papers), Immunotherapy and Immune Responses (9 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Amanda L. Huff collaborates with scholars based in United States, United Kingdom and France. Amanda L. Huff's co-authors include Jill Thompson, Matthew Schuelke, Laura Evgin, Richard G. Vile, Christopher B. Driscoll, Kevin G. Shim, José S. Pulido, Phonphimon Wongthida, Jason M. Tonne and Tim Kottke and has published in prestigious journals such as Nature, Nature Communications and SHILAP Revista de lepidopterología.

In The Last Decade

Amanda L. Huff

17 papers receiving 264 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amanda L. Huff United States	9	182	113	107	100	32	17	267
Matthew Schuelke United States	9	186 1.0×	122 1.1×	118 1.1×	101 1.0×	19 0.6×	10	290
Hong-My Nguyen United States	10	179 1.0×	156 1.4×	129 1.2×	83 0.8×	37 1.2×	17	331
Mubeen Mosaheb United States	6	155 0.9×	103 0.9×	209 2.0×	129 1.3×	18 0.6×	8	377
Emma J. West United Kingdom	10	189 1.0×	196 1.7×	123 1.1×	132 1.3×	24 0.8×	22	360
Sarah Aref United Kingdom	4	80 0.4×	104 0.9×	63 0.6×	47 0.5×	39 1.2×	4	213
Nina Poliak United States	4	123 0.7×	76 0.7×	194 1.8×	128 1.3×	54 1.7×	7	368
Keri A. Streby United States	9	201 1.1×	245 2.2×	129 1.2×	54 0.5×	89 2.8×	16	360
Marcel Silva Luz Brazil	7	83 0.5×	63 0.6×	50 0.5×	71 0.7×	17 0.5×	19	225
Alexandra Miggelbrink United States	5	136 0.7×	60 0.5×	137 1.3×	152 1.5×	26 0.8×	6	320

Countries citing papers authored by Amanda L. Huff

Since Specialization

Citations

This map shows the geographic impact of Amanda L. Huff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amanda L. Huff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amanda L. Huff more than expected).

Fields of papers citing papers by Amanda L. Huff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amanda L. Huff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amanda L. Huff. The network helps show where Amanda L. Huff may publish in the future.

Co-authorship network of co-authors of Amanda L. Huff

This figure shows the co-authorship network connecting the top 25 collaborators of Amanda L. Huff. A scholar is included among the top collaborators of Amanda L. Huff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amanda L. Huff. Amanda L. Huff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Huff, Amanda L., Anna Ferguson, Jiayun Lu, et al.. (2024). Abstract CT022: Mutant KRAS peptide-based vaccine in patients at high risk of developing pancreatic cancer: Preliminary analysis from a phase I study. Cancer Research. 84(7_Supplement). CT022–CT022. 7 indexed citations

Huff, Amanda L., Jacob T. Mitchell, Emily F. Davis-Marcisak, et al.. (2023). CD4 T cell–activating neoantigens enhance personalized cancer vaccine efficacy. JCI Insight. 8(23). 14 indexed citations

Montagne, Janelle M., Thomas R. Nirschl, Emily F. Davis-Marcisak, et al.. (2023). Barcoding intracellular reverse transcription enables high-throughput phenotype-coupled T cell receptor analyses. Cell Reports Methods. 3(10). 100600–100600. 1 indexed citations

Huff, Amanda L. & Neeha Zaidi. (2023). Vaccine boosts T cells that target pancreatic tumours. Nature. 618(7963). 37–38. 2 indexed citations

Baretti, Marina, Brian H. Ladle, Julie M. Nauroth, et al.. (2023). 641 A pilot study of a DNAJB1-PRKACA fusion kinase peptide vaccine combined with nivolumab and ipilimumab for patients with fibrolamellar hepatocellular carcinoma. SHILAP Revista de lepidopterología. A733–A734. 1 indexed citations

Huff, Amanda L., Emily F. Davis-Marcisak, Thatcher Heumann, et al.. (2023). Abstract LB197: A pooled mutant KRAS peptide vaccine activates polyfunctional T cell responses in patients with resected pancreatic cancer. Cancer Research. 83(8_Supplement). LB197–LB197. 5 indexed citations

Huff, Amanda L., Thatcher Heumann, Anna Ferguson, et al.. (2023). Abstract CT036: Safety and immunogenicity of a first-in-human mutant KRAS long peptide vaccine combined with ipilimumab/nivolumab in resected pancreatic cancer: Preliminary analysis from a phase I study. Cancer Research. 83(8_Supplement). CT036–CT036. 3 indexed citations

Zaidi, Neeha, Amanda L. Huff, Thatcher Heumann, et al.. (2022). Abstract IA013: Intercepting pancreatic cancer development with mutant KRAS-targeted immunotherapy. Cancer Research. 82(22_Supplement). IA013–IA013. 2 indexed citations

Driscoll, Christopher B., Matthew Schuelke, Timothy Kottke, et al.. (2020). APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy. Nature Communications. 11(1). 790–790. 49 indexed citations

10.

Huff, Amanda L., Laura Evgin, Jill Thompson, et al.. (2020). Vesicular Stomatitis Virus Encoding a Destabilized Tumor Antigen Improves Activation of Anti-tumor T Cell Responses. Molecular Therapy. 28(12). 2540–2552. 5 indexed citations

11.

Evgin, Laura, Amanda L. Huff, Phonphimon Wongthida, et al.. (2020). Oncolytic virus-derived type I interferon restricts CAR T cell therapy. Nature Communications. 11(1). 3187–3187. 92 indexed citations

12.

Wongthida, Phonphimon, Matthew Schuelke, Christopher B. Driscoll, et al.. (2020). Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors. Neuro-Oncology. 22(12). 1757–1770. 12 indexed citations

13.

Evgin, Laura, Amanda L. Huff, Timothy Kottke, et al.. (2019). Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment. Cancer Immunology Research. 7(5). 828–840. 13 indexed citations

14.

Pfaller, Christian K., Louis-Marie Bloyet, Ryan C. Donohue, et al.. (2019). The C Protein Is Recruited to Measles Virus Ribonucleocapsids by the Phosphoprotein. Journal of Virology. 94(4). 13 indexed citations

15.

Schuelke, Matthew, Phonphimon Wongthida, Jill Thompson, et al.. (2019). Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity. Journal for ImmunoTherapy of Cancer. 7(1). 188–188. 10 indexed citations

16.

Huff, Amanda L., Phonphimon Wongthida, Timothy Kottke, et al.. (2018). APOBEC3 Mediates Resistance to Oncolytic Viral Therapy. Molecular Therapy — Oncolytics. 11. 1–13. 19 indexed citations

17.

Shim, Kevin G., Shane Zaidi, Jill Thompson, et al.. (2017). Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy. Molecular Therapy. 25(4). 962–975. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact